---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-010508"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:46:08.298890+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioMarin estimates FY2025 revenue ~$3.2B; expects $230-260M ROCTAVIAN asset write-down

## Summary
- Preliminary FY2025 total revenue ~$3.2B, with VOXZOGO contributing ~$920M.
- ROCTAVIAN asset write-down of ~$230-260M in Q4 2025; $0.60-$0.64 non-GAAP EPS impact.
- Excluding write-down, previous FY2025 non-GAAP EPS guidance unchanged.
- Approximately 200M weighted-average diluted shares outstanding assumed.

## SEC filing metadata
- accession: 0001193125-26-010508
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312526010508/0001193125-26-010508-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312526010508/d93149d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-010508
- JSON: https://secwatch.observer/filing/0001193125-26-010508.json
- Plain text: https://secwatch.observer/filing/0001193125-26-010508.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.